An α7‐nicotinic acetylcholine receptor agonist PHA‐543613 can significantly improve ICH‐induced brain injury and improve neurological deficiency by PI3K/Akt signal activation‐mediated repression of glycogen synthase kinase‐3β and β‐catenin stabilization, and wortmannin (a specific inhibitor of PI3K/Akt signal) can notably weaken these brain‐protective effects.40, 43. The gene discussed is AKT1; the disease is injury.